
summari report sale result
acquisitions/divestitur top-lin result came
consensu estim
respect report adjust ep penni
consensu estim print mostli in-
line expect continu improv
nutrit strength med devic mid-single-digit growth
diagnost dx soft epd call
maintain organ sale growth guidanc ex-fx excl
alr/amo adj ep guidanc
growth midpoint regard
guid organ sale growth adj ep
bracket consensu key takeaway today
call includ appear well-posit continu
top-tier larg cap med-tech growth driven sever new product
launch libr perform ahead expectationsboth
us europ confirm rx fast start us icm
behind balanc growth adult ped busi epd
establish pharmaceut divis expect rebound
diagnost see sequenti growth improv
chang estim rais sale estim
estim
maintain adj ep estim
respect maintain price target base
adj ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
forecast includ stj acquisit alr deal amo divestitur
compani prioriti stock list
compani data secur llc estim reuter
sale ep street expect report adjust ep penni
consensu estim guidanc rel model ep upsid
larg reflect higher-than-expect revenu gross margin opex tax rate
essenti in-lin forecast total revenu organ ex-fx
acquisit vs estim beat consensu estim nutrit sale
came ahead consensu estim nutrit sale grew
ex-fx improv growth pediatr adult segment diagnost dx
sale beat consensu forecast dx organ growth slow somewhat
exclud alr acquisit due deceler poc point care
growth alr sale exceed estim driven part strong flu season
medic devic sale also consensu estim organ
growth busi essenti stabl vs epd establish
pharmaceut sale fell shi consensu forecast epd sale
growth slow ex-fx due primarili soft russia
 libr launch strong start ou momentum continu today call provid
updat launch compani libr cgm continu glucos monitor system
manag said pleas earli uptak libr alreadi includ
patient strong start translat sale ahead estim
look ahead said confid deliv libr sale high-end
previous discuss rangewhich could still prove conserv view model
libr adopt ou outsid us continu robust contribut
altogeth ad libr patient per month expect finish year
confirm rx launch see traction one potenti underappreci growth driver
view abt confirm rx icm strong start recal confirm rx abt next-
gen icm devic launch octob compet mdt highli success reveal linq
product confirm rx contribut sale incl us well-abov ww
estim physician spoken expect devic captur share
reveal linq confirm rx smartphon compat elimin need separ
handheld transmitt upset physician aggress price linq
separ note good traction compani ensit precis map system togeth
ep electrophysiolog growth came ex-fx us highest level
stj ep growth recal recent memori
dx busi expect improv sequenti post dx growth ex-fx ex-alr
within mid-single-digit guidanc rang sequenti deceler vs growth ex-
fx q/q deceler larg result slowdown poc core lab busi
 expect growth improv modestli around ex-fx ex-alr full-year dx
guidanc mid high-singl digit growth ex-alr impli acceler greater contribut
alin
epd fall short expect bounc back epd sale growth deceler
ex-fx short abt epd guidanc high-single-digit shortfal
primarili due soft russia broader market growth slow due channel
disrupt manag expect russian market stabil anticip carryov impact
disrupt outsid russia sens key emerg market remain
healthi india china brazil grew double-digit expect see improv
broader epd busi growth double-digit
nutrit show improv abt nutrit busi grew ex-fx
improv growth pediatr adult segment pediatr growth ex-fx
led perform ou includ strong growth china adult nutrit saw balanc growth across
geographi driven ensur glucerna brand expect overal nutrit
growth low mid-singl digit rang
outlook maintain today call re-affirmed top bottom-lin full-year
guidanc compani continu expect organ sale growth ex-fx ex-alr/amo
regard fx manag expect report sale tailwind littl bp
littl bp benefit driven primarili strengthen euro move full-
year gross margin still expect somewhat sg spend
expect somewhat sale respect bottom-lin left
adj ep guidanc unchang repres growth
midpoint alr expect contribut littl report sale
guidanc introduc manag guid organ growth full-year
guidanc compar previou estim look abt guidanc
busi epd expect grow double-digit nutrit expect grow low mid-singl
digit diagnost expect grow modestli sequenti around ex-fx ex-alr med
devic expect grow mid high-singl digit manag expect fx posit impact
report sale littl current rate expect alr contribut
report sale bottom-lin guid adj ep compar
previou estim consensu
price target nc
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid-singl digit underli
sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
 incom statement million except per share forma stj alr amo good sold fit fit includ includ med-tech fit fit includ expens fx loss expens ep continu ep includ discontinu analysiscost good margin margin fit fit compani report secur llc estim
